nodes	percent_of_prediction	percent_of_DWPC	metapath
Phenindamine—Epinastine—ADRA1A—polycystic ovary syndrome	0.044	0.168	CrCbGaD
Phenindamine—HRH1—Monoamine GPCRs—ADRA1D—polycystic ovary syndrome	0.0404	0.0548	CbGpPWpGaD
Phenindamine—Nortriptyline—ADRA1D—polycystic ovary syndrome	0.0396	0.151	CrCbGaD
Phenindamine—HRH1—Monoamine GPCRs—ADRA1B—polycystic ovary syndrome	0.0393	0.0533	CbGpPWpGaD
Phenindamine—Mirtazapine—ADRA1A—polycystic ovary syndrome	0.0346	0.132	CrCbGaD
Phenindamine—HRH1—Amine ligand-binding receptors—ADRA1D—polycystic ovary syndrome	0.034	0.0461	CbGpPWpGaD
Phenindamine—Nortriptyline—ADRA1B—polycystic ovary syndrome	0.0338	0.129	CrCbGaD
Phenindamine—HRH1—Amine ligand-binding receptors—ADRA1B—polycystic ovary syndrome	0.0331	0.0448	CbGpPWpGaD
Phenindamine—HRH1—Monoamine GPCRs—ADRA1A—polycystic ovary syndrome	0.0298	0.0404	CbGpPWpGaD
Phenindamine—HRH1—Monoamine GPCRs—ADRB3—polycystic ovary syndrome	0.0287	0.0389	CbGpPWpGaD
Phenindamine—Amitriptyline—ADRA1D—polycystic ovary syndrome	0.0275	0.105	CrCbGaD
Phenindamine—HRH1—Amine ligand-binding receptors—ADRA1A—polycystic ovary syndrome	0.0251	0.034	CbGpPWpGaD
Phenindamine—HRH1—Amine ligand-binding receptors—ADRB3—polycystic ovary syndrome	0.0241	0.0327	CbGpPWpGaD
Phenindamine—Amitriptyline—ADRA1B—polycystic ovary syndrome	0.0234	0.0895	CrCbGaD
Phenindamine—Nortriptyline—ADRA1A—polycystic ovary syndrome	0.0227	0.0868	CrCbGaD
Phenindamine—Mirtazapine—ADRB2—polycystic ovary syndrome	0.0206	0.0786	CrCbGaD
Phenindamine—Amitriptyline—ADRA1A—polycystic ovary syndrome	0.0158	0.0602	CrCbGaD
Phenindamine—HRH1—Monoamine GPCRs—ADRB2—polycystic ovary syndrome	0.0155	0.021	CbGpPWpGaD
Phenindamine—HRH1—Amine ligand-binding receptors—ADRB2—polycystic ovary syndrome	0.013	0.0176	CbGpPWpGaD
Phenindamine—HRH1—G alpha (q) signalling events—PTAFR—polycystic ovary syndrome	0.0104	0.0141	CbGpPWpGaD
Phenindamine—HRH1—G alpha (q) signalling events—ADRA1D—polycystic ovary syndrome	0.0101	0.0137	CbGpPWpGaD
Phenindamine—HRH1—G alpha (q) signalling events—ADRA1B—polycystic ovary syndrome	0.00982	0.0133	CbGpPWpGaD
Phenindamine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—PTAFR—polycystic ovary syndrome	0.0093	0.0126	CbGpPWpGaD
Phenindamine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—ADRA1D—polycystic ovary syndrome	0.00903	0.0122	CbGpPWpGaD
Phenindamine—HRH1—Class A/1 (Rhodopsin-like receptors)—NPB—polycystic ovary syndrome	0.00882	0.012	CbGpPWpGaD
Phenindamine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—ADRA1B—polycystic ovary syndrome	0.00878	0.0119	CbGpPWpGaD
Phenindamine—HRH1—GPCRs, Class A Rhodopsin-like—PTGER3—polycystic ovary syndrome	0.00859	0.0116	CbGpPWpGaD
Phenindamine—HRH1—GPCRs, Class A Rhodopsin-like—LHCGR—polycystic ovary syndrome	0.00859	0.0116	CbGpPWpGaD
Phenindamine—HRH1—GPCRs, Class A Rhodopsin-like—PTAFR—polycystic ovary syndrome	0.00804	0.0109	CbGpPWpGaD
Phenindamine—HRH1—GPCRs, Class A Rhodopsin-like—ADRA1D—polycystic ovary syndrome	0.0078	0.0106	CbGpPWpGaD
Phenindamine—HRH1—IL-4 Signaling Pathway—IRS2—polycystic ovary syndrome	0.00776	0.0105	CbGpPWpGaD
Phenindamine—HRH1—GPCRs, Class A Rhodopsin-like—ADRA1B—polycystic ovary syndrome	0.00759	0.0103	CbGpPWpGaD
Phenindamine—HRH1—G alpha (q) signalling events—ADRA1A—polycystic ovary syndrome	0.00744	0.0101	CbGpPWpGaD
Phenindamine—HRH1—Class A/1 (Rhodopsin-like receptors)—PTGER3—polycystic ovary syndrome	0.00736	0.00998	CbGpPWpGaD
Phenindamine—HRH1—Class A/1 (Rhodopsin-like receptors)—LHCGR—polycystic ovary syndrome	0.00736	0.00998	CbGpPWpGaD
Phenindamine—HRH1—G alpha (q) signalling events—GNRH1—polycystic ovary syndrome	0.00692	0.00938	CbGpPWpGaD
Phenindamine—HRH1—Class A/1 (Rhodopsin-like receptors)—PTAFR—polycystic ovary syndrome	0.00689	0.00933	CbGpPWpGaD
Phenindamine—HRH1—IL-4 Signaling Pathway—IRS1—polycystic ovary syndrome	0.00677	0.00918	CbGpPWpGaD
Phenindamine—HRH1—GPCR ligand binding—NPB—polycystic ovary syndrome	0.00672	0.0091	CbGpPWpGaD
Phenindamine—HRH1—Class A/1 (Rhodopsin-like receptors)—ADRA1D—polycystic ovary syndrome	0.00669	0.00906	CbGpPWpGaD
Phenindamine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—ADRA1A—polycystic ovary syndrome	0.00666	0.00902	CbGpPWpGaD
Phenindamine—HRH1—Class A/1 (Rhodopsin-like receptors)—ADRA1B—polycystic ovary syndrome	0.0065	0.00881	CbGpPWpGaD
Phenindamine—HRH1—GPCRs, Class A Rhodopsin-like—FSHR—polycystic ovary syndrome	0.00629	0.00852	CbGpPWpGaD
Phenindamine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—GNRH1—polycystic ovary syndrome	0.00619	0.00838	CbGpPWpGaD
Phenindamine—HRH1—GPCRs, Class A Rhodopsin-like—ADRA1A—polycystic ovary syndrome	0.00575	0.0078	CbGpPWpGaD
Phenindamine—HRH1—GPCR ligand binding—LHCGR—polycystic ovary syndrome	0.00561	0.0076	CbGpPWpGaD
Phenindamine—HRH1—GPCR ligand binding—PTGER3—polycystic ovary syndrome	0.00561	0.0076	CbGpPWpGaD
Phenindamine—HRH1—GPCRs, Class A Rhodopsin-like—ADRB3—polycystic ovary syndrome	0.00554	0.0075	CbGpPWpGaD
Phenindamine—HRH1—Class A/1 (Rhodopsin-like receptors)—FSHR—polycystic ovary syndrome	0.00539	0.0073	CbGpPWpGaD
Phenindamine—HRH1—GPCR ligand binding—PTAFR—polycystic ovary syndrome	0.00524	0.00711	CbGpPWpGaD
Phenindamine—HRH1—GPCR ligand binding—ADRA1D—polycystic ovary syndrome	0.00509	0.0069	CbGpPWpGaD
Phenindamine—HRH1—GPCR ligand binding—ADRA1B—polycystic ovary syndrome	0.00495	0.00671	CbGpPWpGaD
Phenindamine—HRH1—Class A/1 (Rhodopsin-like receptors)—ADRA1A—polycystic ovary syndrome	0.00493	0.00668	CbGpPWpGaD
Phenindamine—HRH1—GPCRs, Class A Rhodopsin-like—MTNR1B—polycystic ovary syndrome	0.00489	0.00663	CbGpPWpGaD
Phenindamine—HRH1—Class A/1 (Rhodopsin-like receptors)—ADRB3—polycystic ovary syndrome	0.00474	0.00643	CbGpPWpGaD
Phenindamine—HRH1—Class A/1 (Rhodopsin-like receptors)—LHB—polycystic ovary syndrome	0.00469	0.00635	CbGpPWpGaD
Phenindamine—HRH1—G alpha (q) signalling events—GHRL—polycystic ovary syndrome	0.00467	0.00633	CbGpPWpGaD
Phenindamine—HRH1—Class A/1 (Rhodopsin-like receptors)—GNRH1—polycystic ovary syndrome	0.00458	0.00621	CbGpPWpGaD
Phenindamine—HRH1—Class A/1 (Rhodopsin-like receptors)—MTNR1B—polycystic ovary syndrome	0.00419	0.00568	CbGpPWpGaD
Phenindamine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—GHRL—polycystic ovary syndrome	0.00418	0.00566	CbGpPWpGaD
Phenindamine—HRH1—GPCR ligand binding—FSHR—polycystic ovary syndrome	0.0041	0.00556	CbGpPWpGaD
Phenindamine—HRH1—GPCR downstream signaling—NPB—polycystic ovary syndrome	0.0038	0.00514	CbGpPWpGaD
Phenindamine—HRH1—GPCR ligand binding—ADRA1A—polycystic ovary syndrome	0.00375	0.00509	CbGpPWpGaD
Phenindamine—HRH1—GPCR ligand binding—ADRB3—polycystic ovary syndrome	0.00361	0.0049	CbGpPWpGaD
Phenindamine—HRH1—GPCR ligand binding—LHB—polycystic ovary syndrome	0.00357	0.00484	CbGpPWpGaD
Phenindamine—HRH1—GPCR ligand binding—GNRH1—polycystic ovary syndrome	0.00349	0.00473	CbGpPWpGaD
Phenindamine—HRH1—Signaling by GPCR—NPB—polycystic ovary syndrome	0.00345	0.00467	CbGpPWpGaD
Phenindamine—HRH1—GPCR downstream signaling—PLEKHG5—polycystic ovary syndrome	0.00343	0.00465	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—ARHGAP30—polycystic ovary syndrome	0.00336	0.00455	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—ARHGAP23—polycystic ovary syndrome	0.00336	0.00455	CbGpPWpGaD
Phenindamine—HRH1—GPCR ligand binding—SCT—polycystic ovary syndrome	0.00335	0.00453	CbGpPWpGaD
Phenindamine—HRH1—GPCR ligand binding—MTNR1B—polycystic ovary syndrome	0.00319	0.00432	CbGpPWpGaD
Phenindamine—HRH1—GPCR downstream signaling—PTGER3—polycystic ovary syndrome	0.00317	0.00429	CbGpPWpGaD
Phenindamine—HRH1—GPCR downstream signaling—LHCGR—polycystic ovary syndrome	0.00317	0.00429	CbGpPWpGaD
Phenindamine—HRH1—Signaling by GPCR—PLEKHG5—polycystic ovary syndrome	0.00312	0.00422	CbGpPWpGaD
Phenindamine—HRH1—Class A/1 (Rhodopsin-like receptors)—GHRL—polycystic ovary syndrome	0.00309	0.00419	CbGpPWpGaD
Phenindamine—HRH1—GPCRs, Class A Rhodopsin-like—ADRB2—polycystic ovary syndrome	0.00299	0.00405	CbGpPWpGaD
Phenindamine—HRH1—GPCR downstream signaling—PTAFR—polycystic ovary syndrome	0.00296	0.00402	CbGpPWpGaD
Phenindamine—HRH1—Signaling by GPCR—PTGER3—polycystic ovary syndrome	0.00288	0.0039	CbGpPWpGaD
Phenindamine—HRH1—Signaling by GPCR—LHCGR—polycystic ovary syndrome	0.00288	0.0039	CbGpPWpGaD
Phenindamine—HRH1—GPCR downstream signaling—ADRA1D—polycystic ovary syndrome	0.00288	0.0039	CbGpPWpGaD
Phenindamine—HRH1—GPCR downstream signaling—ADRA1B—polycystic ovary syndrome	0.0028	0.00379	CbGpPWpGaD
Phenindamine—HRH1—Signaling by GPCR—PTAFR—polycystic ovary syndrome	0.00269	0.00365	CbGpPWpGaD
Phenindamine—HRH1—Signaling by GPCR—ADRA1D—polycystic ovary syndrome	0.00261	0.00354	CbGpPWpGaD
Phenindamine—HRH1—Class A/1 (Rhodopsin-like receptors)—ADRB2—polycystic ovary syndrome	0.00256	0.00347	CbGpPWpGaD
Phenindamine—HRH1—GPCR downstream signaling—PDE3B—polycystic ovary syndrome	0.00255	0.00345	CbGpPWpGaD
Phenindamine—HRH1—Signaling by GPCR—ADRA1B—polycystic ovary syndrome	0.00254	0.00344	CbGpPWpGaD
Phenindamine—HRH1—GPCR ligand binding—GHRL—polycystic ovary syndrome	0.00236	0.00319	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—FLT4—polycystic ovary syndrome	0.00233	0.00316	CbGpPWpGaD
Phenindamine—HRH1—GPCR downstream signaling—FSHR—polycystic ovary syndrome	0.00232	0.00314	CbGpPWpGaD
Phenindamine—HRH1—Signaling by GPCR—PDE3B—polycystic ovary syndrome	0.00231	0.00313	CbGpPWpGaD
Phenindamine—HRH1—GPCR downstream signaling—ADRA1A—polycystic ovary syndrome	0.00212	0.00287	CbGpPWpGaD
Phenindamine—HRH1—Signaling by GPCR—FSHR—polycystic ovary syndrome	0.00211	0.00285	CbGpPWpGaD
Phenindamine—HRH1—GPCR downstream signaling—ADRB3—polycystic ovary syndrome	0.00204	0.00277	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—NPB—polycystic ovary syndrome	0.00204	0.00276	CbGpPWpGaD
Phenindamine—HRH1—GPCR downstream signaling—LHB—polycystic ovary syndrome	0.00202	0.00273	CbGpPWpGaD
Phenindamine—HRH1—GPCR downstream signaling—GNRH1—polycystic ovary syndrome	0.00197	0.00267	CbGpPWpGaD
Phenindamine—HRH1—GPCR ligand binding—ADRB2—polycystic ovary syndrome	0.00195	0.00264	CbGpPWpGaD
Phenindamine—HRH1—Signaling by GPCR—ADRA1A—polycystic ovary syndrome	0.00193	0.00261	CbGpPWpGaD
Phenindamine—HRH1—GPCR downstream signaling—SCT—polycystic ovary syndrome	0.00189	0.00256	CbGpPWpGaD
Phenindamine—HRH1—Signaling by GPCR—ADRB3—polycystic ovary syndrome	0.00185	0.00251	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—PLEKHG5—polycystic ovary syndrome	0.00184	0.0025	CbGpPWpGaD
Phenindamine—HRH1—Signaling by GPCR—LHB—polycystic ovary syndrome	0.00183	0.00248	CbGpPWpGaD
Phenindamine—HRH1—GPCR ligand binding—GNAS—polycystic ovary syndrome	0.00181	0.00245	CbGpPWpGaD
Phenindamine—HRH1—GPCR downstream signaling—MTNR1B—polycystic ovary syndrome	0.0018	0.00244	CbGpPWpGaD
Phenindamine—HRH1—Signaling by GPCR—GNRH1—polycystic ovary syndrome	0.00179	0.00243	CbGpPWpGaD
Phenindamine—HRH1—Signaling by GPCR—SCT—polycystic ovary syndrome	0.00172	0.00233	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—PTGER3—polycystic ovary syndrome	0.0017	0.0023	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—LHCGR—polycystic ovary syndrome	0.0017	0.0023	CbGpPWpGaD
Phenindamine—HRH1—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	0.00164	0.00222	CbGpPWpGaD
Phenindamine—HRH1—Class A/1 (Rhodopsin-like receptors)—POMC—polycystic ovary syndrome	0.0016	0.00217	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—PTAFR—polycystic ovary syndrome	0.00159	0.00215	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—ADRA1D—polycystic ovary syndrome	0.00154	0.00209	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—ADRA1B—polycystic ovary syndrome	0.0015	0.00203	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—INHBB—polycystic ovary syndrome	0.00146	0.00198	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—PDE3B—polycystic ovary syndrome	0.00137	0.00185	CbGpPWpGaD
Phenindamine—HRH1—GPCR downstream signaling—GHRL—polycystic ovary syndrome	0.00133	0.0018	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—FSHR—polycystic ovary syndrome	0.00124	0.00169	CbGpPWpGaD
Phenindamine—HRH1—GPCR ligand binding—POMC—polycystic ovary syndrome	0.00122	0.00165	CbGpPWpGaD
Phenindamine—HRH1—Signaling by GPCR—GHRL—polycystic ovary syndrome	0.00121	0.00164	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—RACGAP1—polycystic ovary syndrome	0.00117	0.00158	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—ADRA1A—polycystic ovary syndrome	0.00114	0.00154	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—FST—polycystic ovary syndrome	0.00111	0.0015	CbGpPWpGaD
Phenindamine—HRH1—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	0.0011	0.00149	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—ADRB3—polycystic ovary syndrome	0.0011	0.00148	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—LHB—polycystic ovary syndrome	0.00108	0.00147	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—GNRH1—polycystic ovary syndrome	0.00106	0.00143	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—AKR1C1—polycystic ovary syndrome	0.00102	0.00139	CbGpPWpGaD
Phenindamine—HRH1—GPCR downstream signaling—GNAS—polycystic ovary syndrome	0.00102	0.00139	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—SCT—polycystic ovary syndrome	0.00101	0.00137	CbGpPWpGaD
Phenindamine—HRH1—Signaling by GPCR—ADRB2—polycystic ovary syndrome	0.001	0.00136	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—MTNR1B—polycystic ovary syndrome	0.000967	0.00131	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—FGF18—polycystic ovary syndrome	0.000951	0.00129	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—RBP4—polycystic ovary syndrome	0.000943	0.00128	CbGpPWpGaD
Phenindamine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—polycystic ovary syndrome	0.000939	0.00127	CbGpPWpGaD
Phenindamine—HRH1—Signaling by GPCR—GNAS—polycystic ovary syndrome	0.000928	0.00126	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—YAP1—polycystic ovary syndrome	0.00088	0.00119	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—GAB1—polycystic ovary syndrome	0.000868	0.00118	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—INSR—polycystic ovary syndrome	0.00083	0.00112	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—AKR1C3—polycystic ovary syndrome	0.000789	0.00107	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—TNRC6B—polycystic ovary syndrome	0.000776	0.00105	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—PGR—polycystic ovary syndrome	0.000769	0.00104	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—PLAT—polycystic ovary syndrome	0.000714	0.000968	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—GHRL—polycystic ovary syndrome	0.000714	0.000968	CbGpPWpGaD
Phenindamine—HRH1—GPCR downstream signaling—POMC—polycystic ovary syndrome	0.000688	0.000933	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—ATF1—polycystic ovary syndrome	0.000682	0.000924	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—TCF7L2—polycystic ovary syndrome	0.000665	0.000901	CbGpPWpGaD
Phenindamine—HRH1—GPCR downstream signaling—AKT2—polycystic ovary syndrome	0.000662	0.000897	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—NGFR—polycystic ovary syndrome	0.000629	0.000852	CbGpPWpGaD
Phenindamine—HRH1—Signaling by GPCR—POMC—polycystic ovary syndrome	0.000625	0.000847	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—PRL—polycystic ovary syndrome	0.000623	0.000845	CbGpPWpGaD
Phenindamine—HRH1—Signaling by GPCR—AKT2—polycystic ovary syndrome	0.000601	0.000814	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—ADRB2—polycystic ovary syndrome	0.000591	0.000801	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—GNAS—polycystic ovary syndrome	0.000548	0.000743	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—NCOR1—polycystic ovary syndrome	0.000522	0.000708	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—NRG1—polycystic ovary syndrome	0.000513	0.000695	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—IRS2—polycystic ovary syndrome	0.000439	0.000595	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—LEP—polycystic ovary syndrome	0.00043	0.000582	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—IRS1—polycystic ovary syndrome	0.000383	0.00052	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—POMC—polycystic ovary syndrome	0.000369	0.0005	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—INS—polycystic ovary syndrome	0.000367	0.000498	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—IGF1—polycystic ovary syndrome	0.000355	0.000481	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—AKT2—polycystic ovary syndrome	0.000355	0.000481	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	0.000337	0.000457	CbGpPWpGaD
Phenindamine—HRH1—Signaling by GPCR—IL6—polycystic ovary syndrome	0.000272	0.000368	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—VEGFA—polycystic ovary syndrome	0.000232	0.000314	CbGpPWpGaD
Phenindamine—HRH1—Signaling Pathways—IL6—polycystic ovary syndrome	0.00016	0.000217	CbGpPWpGaD
